Objective To analyze the clinical and biological characteristics of infant acute lymphoblastic leukemia(IALL),and to explore its treatment efficacy and prognostic factors.Methods A retrospective analysis was conducted on 22 children who were first diagnosed with IALL and treated in our hospital from January 2010 to June 2020,morphology,immunology,cytogenetics,and molecular biology(MICM)classification,outcomes and factors affecting prognosis were analyzed.Results IALL accounts for 3.33％of the total number of acute lymphoblastic leukemia(ALL)admitted to our hospital.The median age of 22 cases of IALL was 9 months(range3-11 months)old.All children were B cell ALL,while 10 cases(45.5％)were negative for CD10 expression,and 12 cases(54.6％)were combined with MLL rearrangement(MLLr),19 cases(86.4％)achieved bone marrow complete remission on D19 of induction therapy,12(54.6％)cases with IALL had serious infections during treatment,and 5(22.7％)cases died of infection.Five cases(22.7％)had bone marrow relapse,and the 3-year cumulative relapse rate was 29.6％±11.3％.Children with MLLr were more likely to relapse(P=0.04).The 3-year event free survival(EFS)rate of 22 IALL children was 49.0％±10.8％,and the 3-year overall survival(OS)rate was 49.7％±10.9％.The 3-year EFS rates of children at first diagnosis＜6 months and 6-12 months were 33.3％±19.2％and 54.5％±12.8％respectively(P=0.28).The 3-year EFS rates of CD10-negative and CD10-positive children were 40.0％±15.5％and 56.3％±14.8％respectively(P=0.29).The 3-year EFS rates of MLLr-positive and MLLr-negative children were 33.3％±13.6％and 68.6％±15.1％respectively(P=0.12).Conclusions Due to its special clinical and biological characteristics,IALL has high treatment-related mortality,high recurrence rate,and poor overall survival.The prognosis is even worse for children who are less than 6 months old at diagnosis,CD 10-negative immunophenotype,and MLLr positive.
维普
万方数据